In the K14-HPV16 transgenic mouse model of human papillomavirus (HPV)-associated squamous cell cancers, HPV16 E6 and E7 oncogenes and E1 and E2 regulatory genes are driven by the K14 keratinocyte-specific promoter. HPV transcription varies within the different layers of the epithelium. The correlation between HPV transcription patterns and disease pathogenesis is not well understood. Understanding these patterns is critical to designing and testing new HPV-specific therapeutic strategies. We examined HPV gene expression in homogenous populations of cells microdissected from the stratum basale, stratum spinosum, and stratum corneum of lesions from the transgenic mice using PALM microlaser technology. RNA extracted from each cell layer was subjected to two-step gene-specific RT-PCR and real-time quantitative nested PCR. To ensure specific amplification of spliced transcripts, the primers used for realtime nested PCR spanned the splice sites. High levels of E2 were detected in the basal and suprabasal layers of hyperplastic and dysplastic lesions. E7 and E6* levels increased significantly over time in stratum basale and stratum spinosum. E6** was expressed at much lower levels. We showed that the transgenic mice express correctly spliced E2 transcripts and are suitable as a preclinical model to test a therapeutic strategy using transcriptional regulation by the E2 protein.
We have successfully shown in vitro evidence for the feasibility of an HPV-specific gene therapy approach that does not require an active immune response. This approach consists of transfection of a cytotoxic gene under the transcriptional regulation of the HPV E2 protein and is very effective in killing HPV-infected cells (4) . Testing in animal models is an essential next step in preclinical development and demonstration of safety and efficacy in animals is critical to bringing this new treatment approach to phase I clinical testing.
One of the transgenic mouse models of HPV16-associated neoplasia that is currently available is the K14-HPV16 transgenic model (5) (6) (7) (8) . One of these transgenic lines carries HPV16 sequences from nucleotides (nt) 97 to 6152, including the E6, E7, E1, E2, E4, and E5 open reading frames (ORFs) of the HPV16 genome driven by the human keratin-14 promoter (5, 6) . All of the K14-HPV16 transgenic animals develop hyperplastic and/or dysplastic lesions in several inbred backgrounds. Malignant squamous cell carcinomas are typically observed on the epidermis of the ear, the chest, and the truncal skin (5) (6) (7) (8) . Because this transgene construct contains the E2 gene (5), we predicted that it might be a useful model to test our E2-driven gene therapy approach. The ultimate goal of our gene therapy approach is to effect a true virologic cure. Because HPV infection is initially established and maintained in the basal cell layer of the epithelium, we believe that it will be necessary to specifically eliminate this layer in addition to the other layers to achieve this goal. There is evidence that E2 is expressed in the basal and parabasal cells of human epithelium (9) (10) (11) (12) . To date, no animal model has been characterized that has examined HPV E2 expression at different stages of cancer or precancer or correlated the transcriptional profile of E2 to other molecular changes during pathogenesis.
The ability to investigate HPV gene expression profiles at different stages of precancerous disease and cancer progression is usually limited by the cellular heterogeneity of the lesions. In this study, we developed a specific, fast, and accurate method to characterize HPV gene expression in specific cell populations in vivo. We used laser capture microdissection (LCM) of specific cell layers of the lesional epithelium using the PALM system (P.A.L.M. Microlaser Technologie, Bernried, Germany) that is based on laser microdissection and pressure catapulting (LMPC) technology. Using this method, there is no heat or chemical bond formation that would compromise the integrity of the RNA. LCM was immediately followed by RNA extraction, twostep gene-specific RT-PCR, and quantitation of cDNA using nested real-time PCR, methods specifically designed for quantification of low-abundance transcripts from as few as 1 to 50 or 100 cells (13) (14) (15) (16) (17) (18) (19) . We combined the specificity of gene-specific RT-PCR and the sensitivity of real-time nested PCR to develop a fast, specific, and quantitative assay to analyze the transcriptional profile of a small number of laser microdissected cells.
The goals of our present study were 1) to develop a fast, specific RT-PCR combined with quantitative real-time nested PCR method to perform functional genomics at the level of laser microdissected homogenous cell populations from heterogeneous neoplastic lesions and 2) to establish that lesions developing in the K14-HPV16 transgenic mouse model are similar to human lesions and express HPV16 early genes, including the oncogenes E6, E7, and the correctly spliced E2 gene in the basal and the more superficial layers.
MATERIALS AND METHODS

Transgenic mice and tissue collection
The mice lineages were bred and housed at the animal facility maintained by the UCSF Laboratory Animal Care (LARC) department. The K14-HPV16 transgenic mice in the FVB/N mouse strain background exhibit progressive lesions on the ear and the trunk from birth till 10-12 months (5, 6). Biopsies were collected at ages 2 months, 6 months, and 9 months and immediately frozen in cryovials in liquid nitrogen. Control biopsies were also collected from the wild-type FVB/N mice.
Histology
HPV16 gene expression at different stages of disease progression was analyzed in three different layers of the epidermis: 1) stratum corneum, the keratinized outer layers, (nuclei >15 µm or often anuclear); 2) stratum spinosum, middle layers (nuclei ~12 µm); and 3) basal/suprabasal layers (nuclei <10 µm). As a control, cells were also microdissected from the stromal or dermal layers underlying the basal layers of the epithelium.
Laser microdissection
Sections (7 µm) from frozen mouse tissue biopsies were made using a cryostat, and they were placed on polyethylene napthalate foil-covered slides. The sections were fixed for 1 min in 70% ethanol and rinsed in water for a few seconds. They were then stained with Mayer's hematoxylin for 30 s and then rinsed for 10 s in water, 30 s in 70% ethanol, and 30 s in 95% ethanol. Eosin staining was for 15-30 s followed by 30 s treatments in 70%, 95%, and 100% ethanol. The sections were allowed to dry, and then laser microdissection was performed. The cells were microdissected using the PALM laser capture microscope (P.A.L.M. Microlaser Technologie). The PALM system is based on laser microdissection pressure catapulting (LPC) technology. A high-pressure laser beam ejects the selected sample and catapults it into an Eppendorf cap used with an inverted microscope. There is no heat formation during this process. The laser source is a 337 nm pulsed UVA beam. The focus diameter of the laser can be between 1 and 15 µm depending on the objective used. A slide with sectioned tissue was placed under the microscope, and the cell layer of interest was selected using the computer mouse. The laser cut out the cells, and the captured cells were catapulted into the cap of an Eppendorf tube containing 3.0 µl of mineral oil. These cells were resuspended in a guanidine isothiocyanate-containing buffer (RLT buffer from RNeasy minikit, Qiagen, Chatsworth, CA) with 10 µl/ml β-mercaptoethanol to ensure isolation of intact RNA. Approximately 100 cells were pooled from a specific layer of interest and used for RNA extraction.
RNA quantitation using real-time PCR
Total RNA was extracted from the cells using the RNeasy minikit (Qiagen), according to the manufacturer's instructions. The eluted total RNA was treated with RNase-free, DNase I (Promega, Madison, WI) for 2 h at 37°C. The RNA was then repurified in a 30 µl volume using a second RNeasy column according to the manufacturer's instructions.
Both cDNA synthesis and PCR were performed in a single tube using the 2X SuperScript onestep RT-PCR mix (Invitrogen, Carlsbad, CA), with gene-specific primers and target RNA. The 2X SuperScriptmix consists of Superscript II reverse transcriptase and PlatinumTaq DNA Polymerase. Isolated RNA (5 µl) was used with gene-specific outer primers (Table 1A) designed for nested RT-PCR, flanking the splice sites of the HPV16 genes. cDNA synthesis was performed at 50°C for 30 min and denaturation at 94°C for 2 min, followed by 20 amplification cycles at 94°C for 15 s, 50°C for 30 s, and 72°C for 1 min. As a control, the reactions were also performed without the addition of reverse transcriptase.
Real-time PCR setup: As a control, RNA was extracted from 2 ×10 6 cells from the HPV16 cell line CaSki. CaSki cells contain 300-500 copies of HPV16 genomic DNA (20, 21). Using genespecific inner primers for HPV16 genes and mouse β-actin and a fluorescent probe (Table 1B) , detection of RNA from serial dilutions of cDNA was performed to ensure that it was linear and internally consistent over a large range of RNA concentrations. The correlation coefficient of the RNA concentrations and Ct values for different HPV16 genes were in the range of 0.96-0.98. The primers and the probes were selected using Primer Express 1.0 from ABI/Perkin Elmer (Foster City, CA) (Table 1B) and amplified ~80-120 bp amplicons for each of the genes. The primers and probes for E6, E6*, E6**, and E7 have been described previously (22). The fluorescent probes were labeled at the 5′ end with the reporter dye 6-carboxyfluorescein (6-FAM) and at the 3′ end with a black hole quencher (BHQ).
Quantitative real-time PCR was performed using 2-5 µl of cDNA from the RT-PCR step, in a total volume of 25 µl with 100 nm of gene-specific primers and Taqman probes and the 2X Taqman Universal PCR master mix. The 2X Taqman Universal PCR master mix contains AmpliTaq Gold DNA Polymerase, AmpErase UNG, dNTPs with dUTP, passive reference dye Rox, and optimized buffer components. The different gene transcripts were run in duplicates along with a no-RT cDNA control. Amplification and detection were carried out in optical grade 96-well plates in an ABI prism 7000 Sequence Detection System (ABI/PE) with an initial cycle of 50°C for 2 min and 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
To confirm the specificity of the protocol we used, we also performed RT-PCR and real-time PCR using iScript cDNA synthesis kit and iQ supermix (Bio-Rad Laboratories, Hercules, CA) for real-time PCR. The 2X iQ supermix contains iTaq DNA polymerase. Amplification and detection were carried out in an ABI prism 7000 Sequence Detection System as described above. The results obtained using the enzymes from Bio-Rad Laboratories and ABI were consistent over a broad range of input RNA. To determine whether the amplification signal observed for each gene resulted from the amplification products of expected size, we ran the final reaction products on a 4.0% agarose gel after the real-time PCR run was complete. The size of the fragments was determined by running next to a 20 bp ladder (Bio-Rad Laboratories).
Real-Time PCR data analysis
Results of the real-time PCR data are represented as Ct values, where Ct defines the threshold cycle of PCR at which the amplified product was first detected. ∆Ct represents the difference in Ct values derived from HPV16 gene and the mouse β-actin gene for the lesions at different time points (Table 2) . ∆∆Ct represents the difference between the paired tissue samples, as calculated by the formula, ∆∆Ct = ∆Ct (E6 in stratum basale at 2 months) − ∆Ct (E6 in different layers at different ages). Here, ∆Ct for an HPV16 gene at 2 months in the stratum basale was chosen as an arbitrary constant. A validation test was performed before using the ∆∆Ct method of quantitation to determine that the efficiencies of the target genes and the control reference were approximately equal. The slope of the log input amount vs. ∆Ct for the different HPV16 genes was determined to be <0.1 as required. The n-fold differential expression for HPV16 genes at different stages was calculated as 2 ∆∆Ct according to the "Relative quantitation of gene expression" (User Bulletin #2, Perkin Elmer Applied Biosystems, Inc.) and as described previously (23, 24).
RESULTS
K14-HPV type 16 transgenic mice
The K14-HPV16 transgenic mice were produced by targeting the early genes from HPV16 to the basal cells of the squamous epithelium using a human keratin 14 (K14) promoter or enhancer element (5) . The early genes consist of the oncogenes E6 and E7, the replication factor E1, the transcription factor E2, and the E4 and E5 genes (5, 9, 10).
A broad range of pathology, mostly restricted to the squamous epithelium, was observed in the K14-HPV16 mice as described previously (5) (6) (7) (8) . Figure 1 shows a comparative phenotype of a wild-type FVB/N mouse and a K14-HPV16 transgenic mouse at 9 months of age. The transgenic mice exhibited growth retardation and rarely survived longer than 10 months of age, when compared with the average life span of 12-15 months for wild-type FVB/N mice (Fig. 1A) . The epidermis of the ear and the snout or facial epidermis developed lesions in 100% of the mice observed. A majority of the animals also developed cataracts (Fig. 1B ).
Previous studies (5) (6) (7) (8) have clearly shown that the lesions in the K14-HPV16 transgenic mouse model show characteristic neoplastic progression in the squamous epithelium with advancing age. We examined biopsies from the ears of transgenic mice, since the ears consistently develop increasingly severe lesions, as described previously (5) (6) (7) (8) . Figure 2A shows the ear epithelium of an adult wild-type FVB/N mouse. The mouse epithelium from a wild-type mouse consists of 1-3 cell layers that were microdissected as seen in Figures 2B and 2C. The K14-HPV16 transgenic mouse developed mild to moderate hyperplasia by 1-2 months, seen as mild thickness of the ear skin and the snout skin. The histological analysis ( Fig. 2D) showed an increase in the number of cell layers to 8-10, an increase in thickness of the basal layer with mildly enlarged keratinocytes. The differentiation pattern of the epithelium was normal at this stage. The ear from a 5.5-to 6-month-old mouse exhibited both regions of hyperplasia and mild dysplasia (Fig.  2G ). The hyperplastic regions showed an increase in the size of the cells, and the thickness of the epithelium was increased by three-to fourfold. The adjacent dysplastic areas showed an irregular basal layer with large basaloid cells extending into the granular layer. At this stage, the ear and the snout appeared thickened and rough in texture due to hyperkeratosis and acanthosis. By 9 months of age, the ear and the snout showed extreme hyperkeratosis, acanthosis, and papillomatosis. At this stage, small tumors and highly keratotic lesions were seen on the upper body ( Fig. 1) . Histologically, these lesions showed high-grade dysplasia (Fig. 2J ) or welldifferentiated squamous cell carcinomas. Some high-grade, poorly differentiated carcinomas that were locally invasive were also observed at low frequency (5-8). Metastasis was not observed in older animals because most animals were killed 1 month after onset of visible tumors because of perceived discomfort.
Laser microdissection was performed as described in Materials and Methods based on histology. Figure 2E shows microdissection of basal layers from a hyperplastic epithelium. Figures 2H and 2K show microdissection from dysplastic lesions. Figure 2N shows microdissection of the stratum basale, stratum spinosum, and stratum corneum from the same site, showing our ability to distinctly isolate homogenous population of cell layers.
Quantitative analysis using a small number of microdissected cells
We characterized the expression of HPV16 genes in lesions at different time points and performed functional genomics at the level of three distinct layers of the epithelium: stratum basale, stratum spinosum, and stratum corneum. The transgenic mice were examined at 2 months ( Fig. 2D ), 6 months ( Fig. 2G ), and 9 months (Fig. 2J ) of age.
To ensure specificity, ~20-25 cells were excised from a particular layer in a single microdissection. Comparable sections from the same biopsy were examined at each time point. The cells were microdissected and pooled to yield ~100 cells per cap/tube. This ensured that RNA extracted from every tube resulted from an equal number of homogenous population of cells. At least three biopsies were excised from one animal for each time point, and at least four mice were examined for every age group studied. The RNA extracted from every layer was reverse transcribed twice, and the resulting cDNAs were used for real-time quantitative analysis in duplicate. Each cDNA pool was examined twice using real-time quantitation. To ensure further specificity and sensitivity, we used a RT-PCR, real-time nested PCR procedure.
The RT-PCR step was done using gene-specific outer primers flanking the splices sites for HPV16 genes as shown in Figure 3 . The outer primers for the 880^2708 mRNA spanned either side of the splice junctions. For E1/E2 (Table 1A ) the outer forward primer was at position nt 871 and the reverse was at nt 3080. Amplification of HPV16 genomic DNA using these primers results in a 2209 bp fragment while amplification of a correctly spliced E1/E2 transcript using these primers results in an ~380 bp fragment. The primers were tested using RNA extracted from HPV16-positive CaSki cell line and from cell lines transfected with HPV16 DNA, yielding a 380 bp fragment in each line. These primers were also tested on RNA extracted from 3-5 mm biopsies from tumors and from skin of K14-HPV16 transgenic mice and also yielded a fragment of 380 bp. The amplified 380 bp cDNA was cloned and sequenced to confirm that the sequence spanned the splice junction (data not shown).
For the design of primers for real-time assays for the 880^2708 cDNA, the forward primer started at nt 875 to nt 880 at the 5′ end of the splice junction and the rest of the primer picked up at position nt 2708 to nt 2721. Therefore, the forward primer spanned the splice junction (Fig. 3) . The primers and probes used for quantitative analysis of E6, E6*, E**, and E7 using real-time PCR have been described previously (22). The forward primers for E6* and E6** span the splice sites. To further determine that the amplification signal for each gene corresponded to the correct size amplicons, we ran the final amplification products from the real-time experiment on a gel to confirm the expected size (Fig. 4) . The nucleotide sequence of the amplified products was confirmed and verified (data not shown).
Quantitation of HPV16 gene expression using real-time analysis
Real-time PCR offers a sensitive, efficient, and reliable approach to cDNA quantitation. During the real-time analysis, the fluorescent probe was cleaved by the Taq polymerase upon amplification of the target sample, resulting in the release of the fluorescent dye into the solution.
The Ct value represents a designated threshold for the fluorescence signal observed in real-time and is inversely proportional to the number of copies of the target gene. The larger the starting quantity of the target gene, the earlier a significant increase in fluorescence is observed, hence, resulting in a lower Ct value. A difference of one Ct reflects a twofold difference in the amount of the template. The Ct value, therefore, represents a quantitative measure of the target template.
To measure the amount and quality of RNA added to each reaction as precisely as possible, we used a two-round RT-PCR, comparative real-time PCR method, where we quantified the transcripts of an endogenous gene (β-actin) as an RNA internal control. To control for variation in the quantity and quality of RNA, we used mouse β-actin levels to calculate a relative Ct (∆Ct) for the target genes of interest, that is., E2, E1/E2 spliced form, E7, E6, and the E6* and E6** spliced forms. A serially diluted positive control sample was analyzed by linear regression to determine the sensitivity and linearity of the assay as described in Materials and Methods.
In our study, RT-PCR using gene-specific outer primers was optimized to 20 cycles of amplification and was controlled to ensure that there was no no-linear amplification, but produced adequate template for subsequent nested PCR. Depending on the amount of input cDNA, the fluorescence signal reached a threshold resulting in a specific Ct value. To perform quantitative analysis of the Ct values generated by these assays, we used the comparative Ct method (separate tubes) described in User Bulletin #2: ABI prism 7700 Sequence Detection System (see Materials and Methods). This method is used for relative quantitation and is similar to the standard curve method. This bulletin describes the formulas that we used to derive the ∆∆ Ct calculations for relative quantitation using the comparative Ct method. As described in Materials and Methods, a validation test for the target amplification and the control reference amplification was performed to ensure that the ∆∆ Ct method was valid. To determine whether the various amplicons had approximately the same efficiency, Ct values were determined using a wide range of template dilution series. Before using the ∆∆ Ct calculations, we determined that the slope of log input amount vs. ∆ Ct was <0.1 for the amplicons tested, showing that their efficiencies of amplification were approximately equal. According to the User Bulletin #2, once this test is proven, ∆∆ Ct calculations can be used for relative quantitation of target genes without performing standard curves on the same plate.
Results of the real-time PCR data are represented as Ct values in Table 2 , where Ct defines the threshold cycle of PCR at which the amplified product was first detected. ∆Ct represents the difference in Ct values derived from that of a HPV16 gene and the control reference mouse β-actin for different epithelial layers, stratum basale, stratum spinosum, and stratum corneum (Tables 3A, 3B ). The various genes were examined in the different layers at ages 2 months, 6 months, and 9 months. ∆∆Ct represents the difference between the paired tissue samples, as calculated by the formula, for example, ∆∆Ct = ∆Ct of HPV16 gene in stratum basale at 2 months − ∆Ct in different layers at various ages (Tables 3A, 3B) , where ∆Ct of a HPV16 gene at 2 months in the stratum basale is selected as an arbitrary constant and the ∆Ct for the same gene in lesions of different ages in the different layers are subtracted from it. The n-fold differential expression for a gene for different layers at various ages is calculated as 2 ∆∆Ct . The expression of each transcript examined at 2 months in the stratum basale is expressed as 1, and the expression at different ages in the different layers for that gene is expressed relative to that.
The comparative calculations, as shown in Tables 3A and 3B , demonstrate differential expression of various HPV16 genes. Table 3A shows that a relatively large amount of the correctly spliced E1/E2 transcripts were expressed at the ages of 2 and 6 months in the stratum basale. The stratum spinosum at the same age expressed approximately half the stratum basale level of E1/E2 transcripts. At 9 months, the expression of E1/E2 in the stratum basale was reduced to one-fifth of that observed in the stratum basale at 2 months. And the expression in the stratum spinosum was substantially reduced. Very little expression was observed in the stratum corneum at all ages.
The proposed model for HPV16 gene expression in viral infections of human epithelium, suggests that the E2 gene is disrupted or deleted during malignant progression (9-12, 21). Using primers and probes within the E2 ORF and at the 5′ end or the splice junction, we examined E2 expression levels and also the correctly spliced E1/E2 expression levels. The data (Table 2) show that the pattern of expression of E2 was the same as that for E1/E2 transcripts, although E2 showed a relatively higher expression. HPV16 early genes are expressed as polycistronic messages and E2 is part of many of these transcripts (25-28). Because only the correctly spliced forms at the E1/E2 junction will produce the correct protein, we consider the quantitative measure of E1/E2 transcripts to be a more useful measure of E2 gene expression.
In contrast to the E2 transcripts, E7 transcripts increased by 7-fold in the stratum spinosum with increasing age of the mice (Table 3A ). An increase of 3.4-fold was also observed in the stratum basale by 9 months age when compared with the stratum basale of a hyperplastic lesion at 2 months. A much reduced expression was found in stratum corneum at all ages. Table 3B shows the relative expression of the full-length E6 gene and the two spliced forms E6* and E6**. The full-length E6 form showed a slight increase in the stratum spinosum with age. The E6* transcript was the most prominent transcript and increased by 7.5-and 6-fold by 6 and 9 months, respectively, in the stratum spinosum when compared with the expression in the stratum basale at 2 months. There was also an increase in E6* transcripts in the stratum basale of a dysplastic lesion at 6 months. The E6** transcript was expressed at low amounts at all ages.
All the HPV16 early genes examined were expressed at either very low or insignificant amounts in the stratum corneum. None of the genes were expressed or detected in the stroma or dermal layers and no HPV16 gene expression was detected in control biopsies from wild type FVB/N mice (data not shown).
DISCUSSION
HPV16 is the prototype of oncogenic HPVs that results in genital precancerous and cancerous lesions. The viral genome is actively transcribed in lesions, tumors, and cell-lines containing HPV16 genomic DNA. The early and late viral genes are transcribed as a large number of polycistronic messages generated by alternative splicing (25, 26). Most mRNAs generated from the HPV16 promoter p97 contain ORFs of the oncogenes E6 and E7, including the full-length E6 and the alternatively spliced transcripts E6* (nt 226/nt 409) and E6** (nt 226/nt 526). Similarly, a number of alternatively spliced mRNAs with the full-length ORF encoding the viral E2 protein have been identified. Studies have shown that the various spliced transcripts are translated into their respective proteins at different efficiencies (27, 28). Alternative splicing of a number of E2-encoding transcripts may be one of the mechanisms by which E2 protein levels are regulated.
The HPV E2 protein is the sole HPV regulatory transcription factor. The expression pattern of E2 is complex and the mechanisms by which E2 autoregulates its own expression, and the expression levels of the E6 and E7 oncogenes during cancer progression are not well elucidated (11) . Integration or disruption of E2 gene may be one of the determining factors for malignant progression (29-31). The current consensus is that low levels of E2 at early stages of viral infection are required for maintaining early gene expression in the basal and suprabasal layers of the epithelium. At later stages, an increase in E2 expression represses the p97 promoter and the oncogene expression, while the late promoters are activated in the differentiated layers. During neoplastic progression, the expression of E2 is disrupted by either integration into the human genome, resulting in interruption of the E2 ORF by rearrangements or possibly by mutations within the E2 sequence (9, 10, 29-32). This leads to excessive expression of E6 and E7, which inactivate the host tumor suppressors p53 and Rb, respectively (33-37). This may lead to uncontrolled hyperproliferation and host chromosomal instability, resulting in high-grade intraepithelial neoplasia and further progression to cancer (38).
In this study, we characterized the expression of HPV16 early genes E2, E6, and E7 in lesions of K14-HPV16 transgenic mice using two-step, gene-specific RT-PCR combined with real-time nested PCR on the cDNAs generated. The nested quantitative real-time PCR strategy is currently favored for quantification of multiple low-abundance transcripts, for example, 2 femtograms of RNA (13) . The two-step RT-PCR, nested real-time PCR has proven to be particularly sensitive and reliable for studies using RNA from single cells (18, 19) , with a throughput level comparable to low-density microarray hybridization (13) . A recent study by Jiang et al. (14) also describes a two-round, quantitative, real-time, nested PCR method for early diagnosis of SARS-coronavirus infection with <10 viral copies in number. The methodology used is very similar to ours, including initial RT-PCR with gene-specific primers for 25 cycles in the linear range of amplification, followed by real-time nested PCR. Several other studies have also shown the advantages and the sensitivity of the real-time nested PCR for clinical diagnostic purposes (15) (16) (17) .
We examined the expression of HPV16 early genes E2, E6, and E7 in lesions of different ages and performed functional genomics at the level of three distinct layers of the epithelium: stratum basale, stratum spinosum, and stratum corneum. The K14-HPV16 transgenic mice were examined at 2 months, 6 months, and 9 months of age. Large amounts of E2 gene expression were detected in the basal, suprabasal, and stratum spinosum layers of hyperplastic and dysplastic lesions. No E2 was detected in the differentiated stratum corneum layer of the epithelium or in the stroma at any age. At 9 months, there was still some low level E2 expression even in the older lesions. This observation is different from that predicted in human disease. We expected this because in the transgenic mice, the regulation of HPV genes is under the control of the K14 promoter instead of the endogenous HPV promoter. In addition, the HPV genes are always in an integrated form in the mouse genome. In contrast, in human disease consisting of mild dysplasia, the HPV genome is predicted to be mostly episomal with integration occurring at more advanced stages of dysplasia and cancer, leading to loss of E2 expression. In our analysis, the E6 and E7 oncogenes were expressed at higher levels than E2 in all layers of the epithelium. Different spliced variants of E6 were also detected, with E6* being the predominant form at all stages and an E6** transcript detected at low levels. The levels of E7 transcripts especially increased with age.
Coussens et al. (6) examined E6 and E7 gene expression using in situ mRNA hybridization in the K14-HPV16 transgenic line. They used an ~750 bp fragment encompassing the entire E6 and E7 as a probe. Their results showed a threshold expression of E6/E7 mRNA in the hyperplastic lesions, with a mild increase in the dysplastic lesions and a much larger increase in the various cancers. However, this study was not quantitative and the use of a full-length E6/E7 encompassing probe was not able to differentiate between E6 and E7 genes or between the different spliced forms of E6. Another study (8) examined a similar transgenic line in which the K14 promoter was upstream of the E6/E7 oncogenes. They performed RT-PCR with primers that could detect full-length E6/E7 (480 bp) and the two spliced forms E6*/E7 (297bp) and E6**/E7 (180 bp). They extracted RNA from the skin of a 3-day-old mouse (neonate) and a mouse older than 6 months (adult) and by RT-PCR showed that the E6*/E7 spliced transcript was the most abundant in the adult mice and the E6**/E7 transcript was very weakly detectable. The fulllength unspliced E6/E7 was expressed at high levels in the neonate but was weakly detected in the adult due to subsequent splicing events. This observation is similar to what we observed for the various E6 transcripts and the E7 transcripts. The phenotypes of the mice in these studies (5, 7, 8) , showed that the expression of the oncogenes E6 and E7 only is sufficient to induce progressive squamous epithelial neoplasia. Arbeit et al. (5) observed that the transgenic mice expressing the entire early region, including E1 and E2 genes, resulted in as severe a phenotype as observed in some lines that expressed only E6 and E7. However, none of these studies examined HPV16 gene expression in transgenic mice expressing the entire early gene region nor did they examine E2 expression.
In our study, we observed that the E2 gene was expressed consistently regardless of the age of the lesion. A higher level of expression was observed in the basal layers of the early hyperplastic lesions when compared with the stratum spinosum or in the older lesions. The levels of the mature E6* and the E7 transcripts increased progressively over time especially in the stratum spinosum. This led to an increase in the ratio of E6/E7 to E2 transcript levels over time. This is similar to what is observed in human disease, although we did not observe a complete absence of E2 expression in the older lesions (39). The E6/E7 transcripts were constantly expressed by the K14 promoter in the basal layer, which is constantly dividing, leading to an accumulation of the oncogenes in the stratum spinosum.
In summary, we showed that the K14-HPV16 transgenic mice expressed correctly spliced E2 transcripts and are suitable to be used as a preclinical model to test our E2-regulated gene therapy strategy. This strategy has been described previously and shown to be effective in vitro (4) . In previous work, we showed that we could effectively deliver a plasmid carrying the enhanced green fluorescent protein (EGFP) to various layers of the epithelium using topically applied lipoplexes (Sethi et al., unpublished results) . In that study, we used laser microdissection coupled with real-time PCR to confirm the delivery of exogenous plasmid DNA to the basal layers of the epithelium. Using this fast, specific method of nested reverse transcription coupled with gene-specific real-time PCR, we can determine transcriptional profile of a number of viral and host genes simultaneously using 50-100 laser microdissected homogenous population of cells. With the demonstration of correctly spliced E2 in the stratum basale and stratum spinosum, the work described here supports the in vivo feasibility of this gene therapy approach. If shown to be safe and efficacious in mice, this therapeutic approach may be a valuable approach to treating HPV infection in the anogenital tract. Table 1A HPV16 gene-specific outer primers used for reverse transcription E7, E6, E6,* E6** NSRTE6E7-3, forward 5'-GTTACCACAGTTATGCACAGA-3' NSRTE6E7-5, reverse 5'-GGTACCTGCAGGATC-3'
E1/E2
NSE1RT, forward 5'-GATCCTGCAGGTACCA-3' NSE2-9, reverse 5'-CATCCTGTTGGTGCAG-3' E2 NSE2-4, forward 5'-GTATGGGAAGTTCAT-3' NSE2-5, reverse 5'-CTTAGTGGTGTGGCAG-3' Actin mActin, forward 5'-CCTGGAGAAGAGCTATGAG-3' mActin, reverse 5'-ACTTCATGATGGAATTG-3 Table 1B HPV16 primers and probes used for real-time PCR a Gene expression was examined in ear biopsies from 2-month-, 6-month-, and 9-month-old transgenic mice. In each tissue, gene expression was determined in three distinct layers of the epitheliumstratum basale, stratum spinosum, and stratum corneum. Reverse transcription (RT) was performed using gene-specific primers, and cDNA levels were determined using real-time PCR as described in Materials and Methods. Mouse β-actin cDNA levels were used as a control for cellular gene expression. At least three biopsies were collected from four mice for every age group. RT was performed twice, with RNA extracted from each pool of laser microdissected cells, and cDNA thus amplified was quantitated twice in duplicates by real-time PCR.
E7 forward
Page 17 of 23 (page number not for citation purposes) Cryostat sections from the ear epithelium were done on slides covered with a plastic membrane for laser capture microscopy using the PALM system. The sections were stained with hematoxylin and eosin as described in Materials and Methods. We microdissected the different epithelial layers (magnification: 200×), and the microdissected layers were catapulted and isolated into a plastic cap (magnification: 40×) and further used for RNA extraction. Hematoxylin and eosin-stained tissue is red in color. The ear epithelium from a wild-type FVB/N mouse is shown pre-microdissection (A) and post-microdissection (B), and dissected cell layers (C) are shown. The hyperplastic epithelium of a 2-month-old K14-HPV16 transgenic mouse is shown pre-microdissection (D) and post-microdissection of the stratum basale (sb) (E), and the dissected basal layer (F) is shown. Dysplasia by 6 months is seen in pre-microdissection (G) and post-microdissection of the basal layer (H), and the dissected basal layers (I) are shown. High-grade dysplasia by 9 months is seen in premicrodissection (J) and post-microdissection of the basal and suprabasal layers(K), and the dissected basal layers (L) are shown. M) 400× magnification of a hyperplastic lesion and microdissection of stratum basale (sb), one to two cell layers in thickness. N) Distinct microdissection of all three layers, stratum corneum (sc), stratum spinosum (ss), and stratum basale (sb), from the same site is shown. O) Pooling of multiple layers from a specific layer in one cap. The arrows point to the sites of microdissection or to the catapulted cell layers in the cap. 3 . Expected splicing events for the HPV16 early genes. In the K14-HPV16 transgenic mice, the early genes from HPV16, that is, E6, E7, E1, E2, and E5, are driven by a K14 promoter, and the entire cassette is integrated into the mouse genome. The reverse transcription (RT) was performed using gene-specific outer primers as described in Materials and Methods. The cDNAs thus obtained were used as templates for real-time PCR using internal nested genespecific primers and probes as shown in the figure. The primers used for real time are shown as red arrows, and the probes are shown as red bars. 
